Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (75 of 100 Patients Treated)
Expected to complete enrollment at the end of 2024
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

Theralase Technologies Inc. > FYI - updated corp presentation dated Sept 2021
View:
Post by DJDawg on Sep 05, 2021 9:56am

FYI - updated corp presentation dated Sept 2021

Hi all. Hope you are having a good weekend.

You may have noticed, corp presentation updated recently.

https://theralase.com/wp-content/uploads/2021/08/Corporate-PPT-09213.pdf

Some cleaner presenation slides on some of the topics. Nicer slides updating the hope around GBM and NSCLC treatment.

Interesting, the timelines on slide 13, show some hope that BTD might be achieved in window of late late 2021 till mid 2022.
Comment by Oilminerdeluxe on Sep 05, 2021 10:52am
Alsoon slide 13  "Partner with Big Pharma To Commercialize"
Comment by enriquesuave on Sep 05, 2021 10:54am
Accelerated Approval option not shown, as that would depend on data at 450days on 25 patients, plus the interim data on patients 26 and on. iMO  I'm guessing about 12 -18months after BTD, so possibly late 2022 until mid 2023 if that option becomes available on impressive data.  ( very possible if optimized treatments continue to show high and durable efficacy). All IMHO but looking ...more  
Comment by menoalittle on Sep 05, 2021 12:19pm
okay... maybe somebody can help me out with what might be something I'm quite puzzled by on page 15 of that presentation. How do they know (and can say) this? Is this something they've tested/observed in vitro? If so, how do they know (or have controls to determine) what really is or isn't the cause of cancer cell death? Or... by what other means (aside from live testing in humans ...more  
Comment by DJDawg on Sep 05, 2021 2:08pm
I'm no expert but from what I've read, there are many cell culture lines for different cancers. You can make them grow in a lab dish. You can measure the cell activity using markers or cell number or mass. If you test an intervention, you always have the exact same cells as a control comparison in an untreated dish. Other ways to test are to have rodents with transplanted human tumours ...more  
Comment by Yajne on Sep 05, 2021 12:14pm
Thanks DJDawg for drawing attention to the new corporate deck. Lots of great commentary from others on the details, but what hasn't yet been discussed is the reason for the new update at this time. In pre-covid days, companies would typically spend the time on a new deck when preparing for an investor 'road show' or the AGM. The AGM has long passed so are they presenting to potential ...more  
Comment by Eoganacht on Sep 05, 2021 1:48pm
Thanks for letting us know DJDawg. One line I noticed in the presentation: "67% Complete Response (“CR”), 2 out of 3 patients are CANCER FREE up to 730 days post primary treatment. Patient 6 was treated on February 7, 2018. If you add 730 days to this date you get February 7 2020 - exactly 2 years later. Patient 5 was also still CR at this date so this was probably the last time Theralase ...more  
Comment by Oden6570 on Sep 06, 2021 5:03am
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT



Investor Presentation

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 75 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 72 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250